Bringing Microbiome
Into The Clinic
Unlocking the Microbiome to Improve Health
Bringing Microbiome
Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.
AS FEATURED IN
Services
Bio-Me offers a range of proprietary solutions to support research and development of microbiome-based information.
Analysis Services
PMP Analysis Services provides rapid and detailed microbiome analysis rivaling the costs of 16S and the detail of shotgun sequencing with direct quantification, not relative abundance.
Custom Assays
PMP Custom Assays is a flexible solution that makes it possible to tailor-make the specific target bacteria in the assay to the particular need of your specific research needs.
Sequencing Validation
PMP Sequencing Validation is a service offered by Bio-Me where samples that have been sequenced with Shotgun/Whole Genome sequencing approaches can be validated in a standard and highly reproducible qPCR format.
Innovation
The PMP platform technology combined with access to world-leading BioBanks opens up for many exciting microbiome-based clinical applications.
Biomarker Discovery
PMP Biomarker Discovery capitalizes on Bio-Me’s comprehensive health database, with access to information from 15,000 subjects, each with more than 6000 different health parameters.
Diagnostic Applications
PMP Diagnostic Applications includes help to stratify patients in clinical trials, which typically results in higher success rates as well as the development of Companion Diagnostics and disease-specific diagnostics.
Functional Analysis
PMP Functional Analysis includes Biomarker discovery and validation combines PMP with data from world-class microbiome Biobank data through our unique collaboration with the HUNT BioBank. Bio-Me also develops technology which can be used for Drug target discovery and validation.
PARTNERS
Latest news
Bio-Me secures NOK 10 mill in financing
Bio-Me today announced that it has successfully raised NOK 10 mill in a fully subscribed funding round. Both existing and new investors participated in the financing round, with new investors contributing to the majority of the capital. Read More
10 June, 2021
Bio-Me and Siolta Therapeutics to collaborate on developing microbiome-based pediatric allergy and asthma test
Bio-Me and Siolta Therapeutics aim to develop and market predictive test for infants.
Read More23 November, 2020
Bio-Me strengthens Board of Directors to focus on clinical development of microbiome profiling tests
Bio-Me today announced that a new Board of Directors has been approved by the general assembly.
Read More13 July, 2020
Bio-Me strengthens their team with the hire of a Chief Clinical Officer
Runar Vige has taken on the role of Chief Clinical Officer. Runar brings more than 20 years of broad interdisciplinary experience working with companies like Pfizer, Pronova BioPharma, and BASF.
Read More05 June, 2020
Bio-Me receives 2 million Euro in public funding
Bio-Me has received 2 million Euro in grants and public support from The Research Council of Norway to develop a companion diagnostic test for immune checkpoint inhibitor cancer treatments.
Read More23 April, 2020
Bio-Me part of unique Nordic IBD initiative
Bio-Me is one of the participants in a new Nordic project that will develop personalized treatment for IBD patients.
Read More12 August, 2019
